R&D Reference Number Project Short title Project Full title Recruitment end date
1804569 Predictors of depression in people with Ulcerative Colitis – Version 1 Prospective cohort study to identify causes of depression and how depression leads to relapse in people with ulcerative colitis 01/08/2018
1609306 GAST 5438 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, with a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy 11/08/2018
1507119 Study of Immune Drug Side Effects-SIDEFX. Version 1.0 01/09/2018
1707456 Efficacy and Safety of Fligotinib in Active Crohn’s Disease Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Fligotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease 30/09/2018
1807651 GS-US-419-4015 Filgotinib in treatment of Small Bowel Crohn’s Disease A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD) 23/10/2018
906278 IBD-GEN Characterising the Genetic Determinants of Inflammatory Bowel Disease 10/11/2018
1711527 GS-US-419 4016 Filgotinib in treatment of Perianal Fistulizing Crohns A Phase 2, double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of Filgotinib in the treatment of Perianal Fistulizing Crohn’s Disease. 30/11/2018
1607279 SPARE A proSpective randomized controlled trial comParing infliximAbantimetabolites combination therapy to antimetabolites monotheRapy and infliximab monothErapy in Crohn’s disease patients in sustained steroid-free remission on combination therapy (SPARE) 31/12/2018
1609302 I­-CARE – IBD Cancer and Serious Infections in Europe I­-CARE – IBD Cancer and Serious Infections in Europe 31/12/2018
1802586 Biomarkers of malignancy from pancreatic cysts Molecular biomarkers in pancreatic cyst fluid to improve diagnostic accuracy and malignancy risk assessment. 31/03/2019
1511174 GAST 4652 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE 01/04/2019
1808667 Testicular Safety of Filgotinib in Males with Ulcerative Colitis A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis 30/04/2019
1508131 GAST 3772 Phase III, Randomized, Multicenter Double-Blind, Double Dummy Study To Evaluate The Efficacy And Safety Of Etrolizumab Compared With Infliximab In Patients With Moderate To Severe Active Ulcerative Colitis Who Are Naive To TNF Inhibitors 09/05/2019
1307805 PANTS Personalised Anti-TNF in Crohns Disease 02/06/2019
1708486 Long Term Safety of Filgotinib in Active Crohn’s Disease A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease 30/11/2019
1206654 PRED 4 – Predicting Serious Drug Side Effects in Gastroenterology PRED 4 – Predicting Serious Drug Side Effects in Gastroenterology 31/12/2019
1712550 PROFILE – personalised medicine in Crohn’s disease PRedicting Outcomes For Crohn’s dIsease using a moLecular biomarkEr (PROFILE) trial 28/02/2020
1708482 M14-533 Ph 3 study in Mod/Severe Ulcerative Colitis Extension study A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC) 20/04/2020
1708483 M14-234 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis 28/04/2020
1608299 IBD Bioresource The UK Inflammatory Bowel Disease Bioresource: Progressing from Genetics to Function and Clinical Translation in Crohn’s Disease & Ulcerative Colitis 01/10/2020
1609307 GAST 5440 A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn’s Disease 30/06/2021
1607270 GAST 4844 A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis 30/09/2021
1511175 GAST 4684 AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLEDIN THE ETROLIZUMAB PHASE III PROTOCOL GA29144 02/07/2022
1511170 GAST 3773 An Open-Label Extension And Safety Monitoring Study Of Moderate To Severe Ulcerative Colitis Patients Previously Enrolled In Etrolizumab Phase III Studies 13/03/2024